Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2007 Nov 16;21(6):413–417. doi: 10.1002/jcla.20212

Determination of urinary enzymes as a marker of early renal damage in diabetic patients

Ali Mohammadi‐Karakani 1,2,3, Solmaz Asgharzadeh‐Haghighi 1, Mahmoud Ghazi‐Khansari 3,✉, Rohollah Hosseini 4
PMCID: PMC6649252  PMID: 18022929

Abstract

Diagnosis of diabetic nephropathy in the early stages is very important since there are no clinical signs or symptoms. Urinary N‐acetyl‐β‐D‐glucosaminidase (NAG) excretion has been recommended as a tubular dysfunction marker that elevates before other markers, such as microalbuminuria and a decrease in creatinine clearance. In this study, we compared excretion of urinary enzymes with other markers that are used routinely in diabetic nephropathy assessment. Urinary NAG, lactate dehydrogenase (LDH), alkaline phosphatase (AP) activities, urea, creatinine, and albumin, with levels of serum glucose and creatinine and whole blood glycosylated hemoglobin (HbA1c) were measured in 32 diabetes mellitus patients and 25 healthy subjects (controls). Notably, urinary NAG, AP, LDH excretion, and microalbuminuria in the diabetic patients group were significantly increased compared to those in the control groups (P<0.001, P<0.05, P<0.01, and P<0.01, respectively). Meanwhile, our results showed that the urinary NAG excretion had the highest sensitivity and specificity (100% and 87.5%, respectively) compared to other markers. We showed that measuring urinary NAG excretion could be useful for the assessment of renal failure in diabetes mellitus patients and confirmed the use of NAG as a routine screening test. J. Clin. Lab. Anal. 21:413–417, 2007. © 2007 Wiley‐Liss, Inc.

Keywords: diabetic nephropathy, urinary enzymes, urinary NAG excretion, microalbuminuria

REFERENCES

  • 1. Price RG. Urinary enzymes, nephrotoxicity and renal disease. Toxicology 1982;23:99–134. [DOI] [PubMed] [Google Scholar]
  • 2. Chew SL, Lins RL, Daelemans R, Nuyts GD, De Broe ME. Urinary enzymes in acute renal failure. Nephrol Dial Transplant 1993;8:507–511. [DOI] [PubMed] [Google Scholar]
  • 3. Burdmann EA, Andoh TF, Lindsley J, Russell J, Bennett WM, Porter G. Urinary enzymes as biomarkers of renal injury in experimental nephrotoxicity of immunosuppressive drugs. Ren Fail 994;16:161–168. [DOI] [PubMed] [Google Scholar]
  • 4. Skalova S, Chladek J. Urinary N‐acetyl‐beta‐D‐glucosaminidase activity in healthy children. Nephrology (Carlton) 2004;9:19–21. [DOI] [PubMed] [Google Scholar]
  • 5. Tassi C, Abbritti G, Mancuso F, Morucci P, Feligioni L, Muzi G. Activity and isoenzyme profile of N‐acetyl‐beta‐D‐glucosaminidase in urine from workers exposed to cadmium. Clin Chim Acta 2000;299:55–64. [DOI] [PubMed] [Google Scholar]
  • 6. Skalova S. The diagnostic role of urinary N‐acetyl‐beta‐D‐glucosaminidase (NAG) activity in the detection of renal tubular impairment. Acta Medica (Hradec Kralove) 2005;48:75–80. [PubMed] [Google Scholar]
  • 7. Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. Int J Clin Pract 2006;60:1471–1483. [DOI] [PubMed] [Google Scholar]
  • 8. Hong CY, Chia KS. Markers of diabetic nephropathy. J Diabetes Complications 1998;12:43–60. [DOI] [PubMed] [Google Scholar]
  • 9. Uslu S, Efe B, Alatas O, et al. Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients. J Nephrol 2005;18:559–567. [PubMed] [Google Scholar]
  • 10. Basturk T, Altuntas Y, Kurklu A, Aydin L, Eren N, Unsal A. Urinary N‐acetyl B glucosaminidase as an earlier marker of diabetic nephropathy and influence of low‐dose perindopril/indapamide combination. Ren Fail 2006;28:125–128. [DOI] [PubMed] [Google Scholar]
  • 11. Jung K, Pergande M, Schimke E, Ratzmann KP, Ilius A. Urinary enzymes and low‐molecular‐mass proteins as indicators of diabetic nephropathy. Clin Chem 1988;34:544–547. [PubMed] [Google Scholar]
  • 12. Hosseini R, Dehpour AR, Rad MH, Rankohi KE. An improved method for evaluation of nephrotoxicity by assay of urinary N‐Acetyl‐á‐D‐glucosaminidase (NAG) activity. Toxicol Mech Methods 1997;7:153–176. [Google Scholar]
  • 13. Salem MA, el‐Habashy SA, Saeid OM, el‐Tawil MM, Tawfik PH. Urinary excretion of n‐acetyl‐beta‐D‐glucosaminidase and retinol binding protein as alternative indicators of nephropathy in patients with type 1 diabetes mellitus. Pediatr Diabetes 2002;3:37–41. [DOI] [PubMed] [Google Scholar]
  • 14. World Health Organization website. Available at: http://www.who.int/diabetes/en. Last accessed: February, 2007.
  • 15. Hong CY, Chia KS, Ling SL. Urinary protein excretion in type 2 diabetes with complications. J Diabetes Complications 2000;14:259–265. [DOI] [PubMed] [Google Scholar]
  • 16. Ibrahim HA, Vora JP. Diabetic nephropathy. Baillieres Best Pract Res Clin Endocrinol Metab 1999;13:239–264. [DOI] [PubMed] [Google Scholar]
  • 17. Kato H, Takashima T, Kishikawa H, Emura S, Ohmori K. The significance of urinary N‐acetyl‐beta‐D‐glucosaminidase for predicting early stage diabetic nephropathy. Int J Clin Pract 1997;51:489–490. [PubMed] [Google Scholar]
  • 18. Ruggenenti P, Fassi A, Ilieva AP, et al. Bergamo nephrologic diabetes complications trial (BENEDICT) investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941–1951. [DOI] [PubMed] [Google Scholar]
  • 19. Thukral SK, Nordone PJ, Hu R, et al. Prediction of nephrotoxicant action and identification of candidate toxicity‐related biomarkers. Toxicol Pathol 2005;33:343–355. [DOI] [PubMed] [Google Scholar]
  • 20. Price RG. The role of NAG (N‐acetyl‐beta‐D‐glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol 1992;38(Suppl 1):S14–S19. [PubMed] [Google Scholar]
  • 21. Perez‐Blanco FJ, Arrabal‐Martin M, Villen I, Zuluaga A, Rodriguez‐Cuartero A. Urinary activity of N‐acetyl‐beta‐glucosaminidase in patients with nephrolithiasis. Nephron 2000;86:518–519. [DOI] [PubMed] [Google Scholar]
  • 22. Rustom R, Costigan M, Shenkin A, Bone JM. Proteinuria and renal tubular damage: urinary N‐acetyl‐beta‐D‐glucosaminidase and isoenzymes in dissimilar renal disease. Am J Nephrol 1998;18:179–185. [DOI] [PubMed] [Google Scholar]
  • 23. D'Amico G, Bazzi C. Urinary protein and enzyme excretion as markers of tubular damage. Curr Opin Nephrol Hypertens 2003;12:639–643. [DOI] [PubMed] [Google Scholar]
  • 24. Piwowar A, Knapik‐Kordecka M, Fus I, Warwas M. Urinary activities of cathepsin B, N‐acetyl‐beta‐D‐glucosaminidase, and albuminuria in patients with type 2 diabetes mellitus. Med Sci Monit 2006;12:CR210–CR214. [PubMed] [Google Scholar]
  • 25. Sanchez‐Hueso MC, Mateo‐Caas J, Zamora‐Madaria E. [Influence of glycemic blood glucose control and incipient diabetic nephropathy on the urinary excretion of N‐acetyl‐glucosaminidase (NAG) in diabetes mellitus] [Abstract]. An Med Interna 1995;12:216–220. [Spanish] [PubMed] [Google Scholar]
  • 26. Kuzuya T, Nakagawa S, Satoh J, et al. Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002;55:65–85. [DOI] [PubMed] [Google Scholar]
  • 27. Oba K, Igari Y, Matsumura N, et al. Effect of control of blood glucose on urinary excretion of N‐acetyl‐beta‐D‐glucosaminidase in elderly type 2 diabetes mellitus. J Nippon Med Sch 2000;67:143–145. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES